中性粒细胞
髓系白血病
医学
伊马替尼
酪氨酸激酶
甲磺酸伊马替尼
费城染色体
内科学
酪氨酸激酶抑制剂
细胞遗传学
阿布勒
肿瘤科
免疫学
癌症研究
生物
染色体
染色体易位
癌症
受体
基因
遗传学
作者
David T. O. Yeung,Michael J. Mauro
出处
期刊:Hematology
[American Society of Hematology]
日期:2014-11-24
卷期号:2014 (1): 240-243
被引量:9
标识
DOI:10.1182/asheducation-2014.1.240
摘要
A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 × 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?
科研通智能强力驱动
Strongly Powered by AbleSci AI